// App-Quantinova.ai

e16527 : Safety and clinical outcomes of GT0918 (Proxalutamide), a potent androgen receptor (AR) blocker, in patients with mCRPC progressing on standard (SoC) and experimental therapies: Phase I/II trial.

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Richard Levin

  • David Chu

  • Nashat Y. Gabrail

  • Luke T. Nordquist

  • Mark N. Stein

  • Harish P. Dave

  • Phoebe Zhang

  • Karl Zhou

Medical Centers

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Chesapeake Urology Research Associates, Baltimore, MD

  • North Shore Hematology Oncology Associates, East Setauket, NY

  • Gabrail Cancer Center, Canton, OH

  • Urology Cancer Center and GU Research Network, Omaha, NE

  • Columbia University Medical Center, New York, NY

  • Linical Accelovance Group, Rockville, MD

  • Suzhou Kintor Pharmaceuticals, Inc., Suzhou, China

  • Suzhou Kintor Pharmaceuticals, Inc., Suzhou, China

Locations

  • United States

  • China

Companies

  • Kintor Pharmaceutica

  • Suzhou Kintor Pharma

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Docetaxel

  • Androgen Tear

  • GT0918

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT0282677250

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved